Chang Gung University

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Retrieved on: 
Wednesday, April 17, 2024
Heart, Average cost, Cardiogenic shock, European Patent Convention, Research, Annual report, Diabetes, Security (finance), Insurance, Partnership, Chang Gung University, Heart failure, IND, Seismology, Family, Patient, White lung, Hypertension, Malignancy, PURE, AHF, Therapy, SCAI, Pharmaceutical industry

WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
  • Research and development expenses were $3.1 million for the fourth quarter of 2023, compared to $1.2 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $1.9 million, compared to $2.2 million for the fourth quarter of 2022.
  • For the fourth quarter ended December 31, 2023, the Company reported an operating loss of $5.0 million, compared to an operating loss of $10.8 million in the fourth quarter of 2022.

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Retrieved on: 
Thursday, February 1, 2024
Partnership, Catecholamine, Mortality, Oxygen, Cardiomyopathy, Research, Heart, Cardiovascular disease, Patient, Prevalence, Windtree Therapeutics, Cardiogenic shock, Sarcoplasmic reticulum, Arrhythmia, Cardiac output, Blood, Brain, Therapy, Kidney, Heart failure, Risk, Cytoplasm, Chang Gung University, Pharmaceutical industry

The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators.

Key Points: 
  • The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators.
  • SERCA2a activity is decreased in heart failure and disordered calcium handling can play a role in cardiac arrythmias.
  • Windtree believes activation of SERCA2a could represent an important advancement in heart failure treatment for patients.
  • Outside of this scientific collaboration, istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock.

ROHM’s New Ultra-High-Speed Gate Driver IC: Maximizing the Performance of GaN Devices

Retrieved on: 
Wednesday, November 8, 2023
Internet of things, ROHM, Department of Electrical Engineering and Information Technology of TU Darmstadt, Rohm, APEX, National Chiao Tung University, NCU, National Taipei University of Technology, BS, DC-DC, JJAP, AC-DC, Research, WLCSP, National Taipei University, Gallium nitride, Pulse, MS, University, Chang Gung University, Japanese Journal of Applied Physics, National Central University, Electricity, Miniaturization, Applied Physics Express, Silicon, Electric motor, Electronics, Lidar

This was facilitated through a deep understanding of GaN technology and the continuing pursuit of gate driver performance.

Key Points: 
  • This was facilitated through a deep understanding of GaN technology and the continuing pursuit of gate driver performance.
  • As these applications require the use of high-speed switching devices, in conjunction with the release of GaN devices, ROHM developed an ultra-high-speed gate driver IC that maximizes GaN performance.
  • As GaN devices are sensitive towards gate input overvoltage, ROHM has developed a unique method to suppress the gate voltage overshoots and has implemented it into this driver.
  • On the other hand, to demonstrate the performance of GaN devices, gate driver IC that enable high-speed switching while taking into account the low drive voltage of GaN HEMTs are essential.

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

Retrieved on: 
Tuesday, November 1, 2022
Honda, Survival, Board of directors, Risk, IPO, California State University, Faculty, Cherokee Nation, SEC, Anhui University, Cancer, Karolinska Institute, Research, Board, RT, Tokyo Medical and Dental University, Nasdaq, University of British Columbia, Immunotherapy, National Coalition for Syrian Revolutionary and Opposition Forces, Cherokee, Lijun International Pharmaceutical (Holding) Co. Ltd., University, National Institute of General Medical Sciences, Radiation, Patient, Audit committee, National, Georgetown University School of Medicine, Ecology, Sciences Po, Georgetown University, Quality of life, Chang Gung University, Georgetown University School of Nursing and Health Studies, Moses Austin, Pharmaceutical industry, Nursing

ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.

Key Points: 
  • ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.
  • Dr. Jacobs will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
  • A voting member of the Cherokee Nation, Dr. Jacobs has lifetime involvement in advancing equity and diversity programs.
  • "I am excited to welcome Dr. Bette Jacobs to the board at Shuttle Pharmaceuticals," Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals, said.

NTHU Post-Baccalaureate Program in Medicine Holds Opening Ceremony

Retrieved on: 
Wednesday, May 4, 2022
Other Health, Health, University, Pharmaceutical, Education, Cloud, List of life sciences, Big data, Department, Hsinchu Science Park, Student, Alphabet song, Taoyuan Aerotropolis, NTHU, Chemical engineering, Time-invariant system, Physician, Information technology, College, Urology, Patient, Materials science, Nephrology, Pharmacology, Program, BYU College of Life Sciences, Artificiality, Department of Medicine – University of Pamplona, Artificial intelligence, Chang Gung University, Precision medicine, International Bilingual School at Hsinchu Science Park, Post, Physiology, Curriculum, Technology, Cardiology, AI, Pathology, Multimedia, Medicine, Medicine

On March 30, NTHU held the opening ceremony for the Post-baccalaureate Program in Medicine, during which NTHU president Hocheng Hong said that the new program will train students to meet the challenges of tomorrow by focusing on the ABCs of the medical science of the future, viz., Artificial intelligence (AI), Big data, and the Cloud-based internet of things.

Key Points: 
  • On March 30, NTHU held the opening ceremony for the Post-baccalaureate Program in Medicine, during which NTHU president Hocheng Hong said that the new program will train students to meet the challenges of tomorrow by focusing on the ABCs of the medical science of the future, viz., Artificial intelligence (AI), Big data, and the Cloud-based internet of things.
  • View the full release here: https://www.businesswire.com/news/home/20220504005503/en/
    The opening ceremony for the Post-baccalaureate Program in Medicine.
  • The Post-baccalaureate Program in Medicine belongs to the College of Life Science, the dean of which is Kao Ruey-ho.
  • The director of the Program will be Chou Hung-hsueh, formerly the director of the Department of Medicine at Chang Gung University.